ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: TH-OR06

Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD)

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Pergola, Pablo E., Renal Associates PA, San Antonio, Texas, United States
  • Charytan, Chaim, New York Hospital Queens, Division of Nephrology, Flushing, New York, United States
  • Little, Dustin J., Clinical Research, AstraZeneca, Gaithersburg, Maryland, United States
  • Tham, Stefan, Clinical Research, AstraZeneca, Gothenburg, Sweden
  • Szczech, Lynda, FibroGen Inc., San Francisco, California, United States
  • Fishbane, Steven, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, United States

Anemia in CKD is multifactorial, with contributions from reduced erythropoietin production and hepcidin-induced functional iron deficiency. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, treats anemia by enhancing erythropoietin synthesis and increasing iron availability via reducing hepcidin and increasing iron transport. We assessed the effect of roxadustat on iron parameters in patients with DD-CKD.


Patients were randomized to open label roxadustat or epoetin alfa in 3 pivotal DD-CKD trials. Intravenous (IV) iron was administered per usual care with epoetin alfa and was limited to rescue therapy with roxadustat. Mean changes from baseline in Hb, hepcidin, and iron parameters were evaluated. Pooled results are reported.


Overall, 3890 patients were evaluated (roxadustat N=1943; epoetin alfa N=1947; mean baseline Hb 9.7 g/dL for both groups), including 1515 incident dialysis patients (roxadustat N=756; epoetin alfa N=759; overall mean baseline Hb values ~8.8 g/dL). Mean Hb increased more from baseline averaged over Weeks 28–52 with roxadustat vs epoetin alfa (1.21 vs 0.95 g/dL; P<0.0001). Roxadustat-treated patients used less IV iron, with mean monthly IV iron use over Weeks 28–52 of 80.3 mg for roxadustat and 108.2 mg for epoetin alfa (P<0.0001). Roxadustat reduced hepcidin and increased transferrin and serum iron; transferrin saturation did not change vs epoetin alfa (Figure). Reduction in ferritin occurred predominantly in patients with the highest baseline values when assessed by quartile (>800 µg/L).


Roxadustat facilitated iron transport and utilization by increasing both iron-carrying capacity (transferrin) and serum iron, in contrast to the effects on these parameters seen with epoetin alfa. Overall, these changes contributed to decreased need for IV iron use while achieving greater Hb increase from baseline with roxadustat vs epoetin alfa.


  • Commercial Support –